Organon & Co. (NYSE:OGN) Short Interest Update

by · The Cerbat Gem

Organon & Co. (NYSE:OGN – Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 15,130,000 shares, a decline of 17.6% from the March 15th total of 18,360,000 shares. Based on an average daily volume of 3,510,000 shares, the short-interest ratio is currently 4.3 days. Currently, 5.9% of the shares of the company are short sold.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Horizon Bancorp Inc. IN boosted its stake in Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares in the last quarter. Millstone Evans Group LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at approximately $29,000. Larson Financial Group LLC increased its position in Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co lifted its stake in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, GeoWealth Management LLC acquired a new stake in Organon & Co. in the fourth quarter valued at approximately $41,000. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on OGN. Morgan Stanley reduced their target price on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Barclays reduced their price objective on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.60.

View Our Latest Research Report on OGN

Organon & Co. Price Performance

Shares of NYSE OGN traded down $0.45 during midday trading on Monday, reaching $10.67. The company’s stock had a trading volume of 4,492,118 shares, compared to its average volume of 2,662,296. The business’s 50 day moving average price is $14.25 and its two-hundred day moving average price is $15.37. The company has a market cap of $2.75 billion, a P/E ratio of 3.20, a P/E/G ratio of 0.90 and a beta of 0.73. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $10.46 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN – Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 10.50%. The ex-dividend date was Monday, February 24th. Organon & Co.’s payout ratio is presently 33.63%.

Organon & Co. Company Profile

(Get Free Report)

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Featured Stories